Int J Biol Macromol 2015;78:3945
Victoza is FDA-approved to help control blood sugar in type 2 diabetes and can also support weight loss off-label
Global impacts of western diet and its effects on metabolism and health: A narrative review
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months #AHA2023 nejm.org/doi/full/10.10 Join the conversation

According to the platform's own published terms of service: "There is no guarantee of results or effectiveness due to your participation in the Subscription Services." The platform also states: "Results may vary
You should never throw pens or vials into the regular household trash, and you should never flush the medication down the toilet